These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 7805931)

  • 1. Mathematical modelling of chemotherapy in HIV infection.
    Hraba T; Dolezal J
    Folia Biol (Praha); 1994; 40(3):103-11. PubMed ID: 7805931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical modelling of immunotherapy in HIV infection.
    Dolezal J; Hraba T
    Folia Biol (Praha); 1994; 40(4):193-9. PubMed ID: 7851617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose, sublingual AZT-monophosphate therapy for HIV+ patients?
    Johnson S
    Med Hypotheses; 2001 Mar; 56(3):409-10. PubMed ID: 11359372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report on a 3-year follow-up zidovudine (AZT) treatment in a group of HIV-positive patients with congenital clotting disorders.
    Sartori MT; Mares M; Zerbinati P; Stocco D; Girolami A
    Haematologia (Budap); 1994; 26(1):17-27. PubMed ID: 7959371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival of patients with advanced HIV infection treated with 300 mg/d of zidovudine: a prospective study.
    Ruiz-Argüelles GJ; Lagunes-Yannelli B; Mercado-Díaz L; Alemán-Hoey DD
    Rev Invest Clin; 1994; 46(6):491-3. PubMed ID: 7899741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studies of zidovudine in combination with didanosine and zalcitabine.
    Jablonowski H
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S52-6. PubMed ID: 8595509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interrelationship between the duration of HIV infection, viral load and CD4 positive lymphocyte count].
    Soriano V; Gómez-Cano M; Castilla J; Villalba N; Holguín A; Bravo R; Mas A; Pérez-Labad ML; González-Lahoz J
    Med Clin (Barc); 1998 Apr; 110(14):529-31. PubMed ID: 9646266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.
    Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M
    AIDS; 2007 May; 21(8):939-46. PubMed ID: 17457087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of zidovudine related mutations in the reverse transscriptase gene of HIV after switching therapy.
    Falkensammer B; El Attal R; Müllauer B; Sarcletti M; Parson W; Dierich MP; Stoiber H
    Eur J Med Res; 2002 Sep; 7(9):379-86. PubMed ID: 12435615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effectiveness of zidovudine].
    Mulder JW
    Ned Tijdschr Geneeskd; 1995 Feb; 139(5):211-3. PubMed ID: 7854480
    [No Abstract]   [Full Text] [Related]  

  • 13. Azidothymidine (AZT) in the treatment of symptomatic HIV-1-infected hemophiliacs.
    Eichinger S; Pabinger I; Hartl H; Stain C; Mayerhofer S; Schweiger C; Kier P; Schwarzinger I; Kyrle PA; Lechner K
    Thromb Haemost; 1990 Aug; 64(1):108-12. PubMed ID: 1980381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
    López-Martínez C; Guarner J; Magis-Rodríguez C; Uribe-Zúñiga P; del Río-Chiriboga C
    Rev Invest Clin; 1998; 50(4):335-9. PubMed ID: 9830323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AZT and 3TC.
    Treat Rev; 1996 Apr; (no 21):4. PubMed ID: 11363395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZT studies reinforce benefits of combination.
    AIDS Alert; 1995 Jan; 10(1):11-2. PubMed ID: 11362167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of 3'azido-3'deoxythymidine-resistant HIV-1 infection by dehydroepiandrosterone in vitro.
    Yang JY; Schwartz A; Henderson EE
    Biochem Biophys Res Commun; 1994 Jun; 201(3):1424-32. PubMed ID: 8024587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells.
    Lapenta C; Santini SM; Proietti E; Rizza P; Logozzi M; Spada M; Parlato S; Fais S; Pitha PM; Belardelli F
    Virology; 1999 Oct; 263(1):78-88. PubMed ID: 10544084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.